GSK has won FDA approval for Jideytro, a drug at the heart of its $10.6 billion acquisition of Nuvalent earlier this year – ...

After a delay of several years, people living with multiple sclerosis in England will finally be able to get NHS access to ...

China has become the first country to approve Takeda's first-in-class orexin agonist, oveporexton, for the sleep disorder ...

Could there be a third big pharma acquisition this week? MSD is rumoured to be in talks to buy Revolution Medicines in a deal that could be worth up to $32 billion. The chatter – first reported by the ...

New guidelines on NHS management of type 2 diabetes will introduce a more personalised approach that could see expanded access to drug treatments, including GLP-1 agonist therapies. The shift from a ...

AI company Anthropic and the Gates Foundation have said they will provide $200 million in funding for a programme to support the development of AI for "health, life sciences, education, and economic ...

Rumours earlier this week of an imminent takeover offer for Day One Biopharmaceuticals proved well-founded, but missed the mark on the identity of the acquirer. France's Servier has emerged as the ...

Novo Nordisk has reported the second phase 3 trial of its new obesity hopeful CagriSema but, as with the first, the topline weight-loss result has sent its shares into a sharp decline. The stock was ...

German biopharma company BioNTech has said it will commit up to £1 billion ($1.34 billion) in investment in the UK over the next decade, including the creation of R&D and artificial intelligence ...

Shares in Novo Nordisk were up nearly 12% today – hiking its valuation to more than $280 billion – after it reported new clinical data with one of its obesity drug candidates. The new results with a ...

Roche's Itovebi was the first PI3K inhibitor to get approved as a first-line treatment for breast cancer last year – and new survival data to be presented at the upcoming ASCO congress looks set to ...

Vinay Prasad has stepped down as head of the FDA's Center for Biologics Evaluation and Research (CBER), less than three months after taking on the role. His departure – first reported by STAT and now ...